Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFAMPIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus RIFAMPIN.
ARIKAYCE KIT vs RIFAMPIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits DNA-dependent RNA polymerase in bacteria, blocking RNA synthesis.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
Oral or IV: 600 mg once daily (10 mg/kg/day). For tuberculosis: 10 mg/kg (max 600 mg) once daily.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
Terminal elimination half-life is 3–5 hours initially, decreasing to 2–3 hours after repeated dosing due to autoinduction of hepatic microsomal enzymes. In hepatic impairment, half-life may increase to 5–8 hours.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Biliary excretion of unchanged drug (60–65%) and metabolites (15–20%); renal excretion of unchanged drug (15–20%) and metabolites (5–10%); fecal elimination of unabsorbed drug (≤5%).
Category C
Category A/B
Antimycobacterial
Antimycobacterial